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Abstract
Epidemics of ergotism occurred frequently in the Middle Ages. They were a source of inspiration for artists and were popularly 
known as ‘St. Anthony’s Fire’, resulting in gangrene, neurological diseases and death. It was caused by eating rye bread con­
taminated with the fungus claviceps purpurea. In 1582 it was described that a delivery could be hastened by administering a few 
spurs o f the secale cornutum. The dosage was, however, very inaccurate resulting in frequent uterine ruptures. The nickname of 
the preparation of ‘pulvis ad partum’ was changed to ‘pulvis ad mortem’. Therefore, after 1828 the ergot alkaloids were no longer 
used during delivery but only as a measure to prevent postpartum haemorrhage. From 1875 onwards many derivatives o f ergot 
alkaloids were found. Dudley and Moir isolated ergometrine in 1932. It proved to have a very specific uterotonic action. However, 
because of severe and unpredictable side effects and the instability of the drug, ergometrine is not the drug o f choice for either 
the prevention or the treatment o f postpartum haemorrhage.
Keywords: St. Anthony’s fire; Claviceps purpurea; Ergot alkaloids; Uterotonic activity; Postpartum haemorrhage
1. Early history
The very fertile crescent of Mesopotamia between the 
Euphrates and Tigris produced the first agricultural set­
tlements around 9000 BC. The wild grasses were 
cultivated and yielded good harvests of grain from 
wheat and rye. Assyria and Babylonia could develop be­
cause of the stable supply of this staple food. However, 
grasses and especially rye can be contaminated by the 
fungus Claviceps ( C) purpurea during wet seasons, pro­
ducing the typical ergot, i.e. the sclerotium, in the ears 
of grain (Fig. 1).
Ergot is probably first mentioned around 600 BC on 
an Assyrian cuneiform tablet as a enoxious pustule in the 
ear of grain’. The Roman historian Lucretius (98-55 
BC) called erysipelas ‘Ignis sacer’, i.e. Holy Fire, which 
name was given in the Middle Ages to ergotism. In one 
of the holy books of the Parsees in the 7th century 
ergotism was described as ‘noxious grasses that cause 
pregnant women to drop the womb and die in childbed5 
[ 1,2 ].
* Corresponding author.
2, Ergotism
Epidemics of ergotism occurred frequently in the 
Middle Ages. It was caused by eating rye bread con­
taminated with C. purpurea3 resulting in gangrene of 
limbs, disturbances in the function of the central ner­
vous system and ultimately death.
Ergot is derived from the old French word argot, 
meaning the cock’s spur. The violet or black sclerotia 
consist of hyphae and are at least three times longer than 
the grains. Before or at harvest time the sclerotia fall on 
the ground and remain inactive till they germinate in the 
next warm and moist spring by developing 15-60 white 
spherical heads on stalks (hence the name claviceps; Fig. 
2). Ascospores are set free by rupture of the head and 
propelled into the air by several cm. Within 8 days the 
infection of the flowering rye causes a secretion, the so- 
called honey-dew, in which the conidia (asexual spores)
develop. This secondary infection leads to the produc­
tion of the mycelium and then to the solid sclerotium, 
closing the lifecycle of C purpurea [3-5].
If bread was prepared without removing the black
spurs, epidemics of ergotism sprang up. Rye was mainly
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Fig. 1. The first illustration of ergot. Woodcut in Caspar Bauhin’s 
Theatrum Botanicum (1685)
eaten by the poor people, especially during famines. The 
suffering from ergotism was then doubled, because the 
spurs were also collected because of hunger. The Rus­
sians in the late Middle Ages considered the spurs as a
. » I.
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necessity to produce good quality bread. The German 
mythology explained the ‘sudden’ appearance of ergot 
by transgression of the ‘Kornmutter’ (mother-grain) 
through fields during foggy weather [1].
The first mentioning of gangrenous ergotism can be 
found in the ‘Annales Xantenses’ (Germany) in 857 AD; 
‘A great plague of swollen blisters consumed the people 
by a loathsome rot so that their limbs were loosened and 
fell off before death’ [6], The first epidemic of convulsive 
ergotism is described in 945 in Paris, France [1]. It was 
accompanied by erythema, diarrhoea, vomiting, for­
mication and agonizing burning sensations as if the 
limbs were burning, often preceded by convulsions, 
catalepsy, dullness or maniacal excitement, hence the 
mentioning of 'dancing epidemics5. Most victims died,
but some who fled to the church of St. Mary or Martial 
survived, most probably because they got non­
contaminated food as was seen in the epidemic of Aqui­
taine, France (994 AD) in which 40 000 people perished 
[1].
The gangrenous type was mostly seen in France and 
the convulsive one in Germany. The two distinct types 
of ergotism (gangrenous and convulsive) may be con­
sidered as acute and chronic varieties of ergotism. The 
different symptoms described are given in Table 1. As 
the formication is typical in the convulsive type, it was 
called ‘Kriebelkrankheit’ in Germany. Mixed types were 
described as well» especially in other European countries 
[2].
3. Holy fire
In 1095 the order of St. Anthony was founded in 
Vienne, France. Especially in the 12th and 13th cen­
turies, people flocked during epidemics to the hospitals
Table 1
Symptoms of ergotism
Fig. 2. Fully developed heads of the claviceps purpurea.
Gangrenous ergotism Convulsive ergotism
Abortion Fatigue
Amenorrhoea Giddiness
Failure to lactate Paraesthesia
Lassitude Formications
Lumbar pain Nausea/vomiting
Calf pain Burning sensation
Feet/hands Clonic/tonic spasms
Swollen Flexion of arms/hands
Vesicles Paralysis, hemi(para)plegia
Inflammation Maniacal excitement
Alternating hot or cold Hallucinations
Livid, black Visual disturbances
Analgesia Delusional insanity
Gangrene Psychosis
Amputation Convulsions
Jaundice Dullness
Severe diarrhoea Cataract
Death Death
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of the Antonines. The bones of the Egyptian hermit St. 
Antony (251-356 AD) were sprinkled with holy water 
and wine and given to the sufferers of ergotism. Soon 
the hospitals were called the ‘hôpitaux des démembrés’ 
because at its entrance the spontaneously amputated 
limbs were exhibited as kinds of ex votos. Due to the 
good treatment by providing non-contaminated bread, 
the popular hospitals spread all over Europe to a zenith 
of 390 settlements [3].
The frequent epidemics were called St. Anthony’s 
Fire, ‘Holy Fire’ or Ignis Sacer because of the burning 
sensations in the limbs, as is depicted in the art of the 
time [7-10]. Victims of ergotism could identify 
themselves easily with the lifelong tortured St. Anthony. 
In the woodcut from 1517 (Fig. 3) a farmer who lost his 
right foot, extends his left arm engulfed in symbolic 
flames towards St. Anthony for help and protection. 
Medieval medicines were thought to restore the balance 
between hot and cold, wet and dry ailments. The Holy 
Fire was of course considered as a very hot disease, 
treatable with cooling elixirs, holy vintage with rare and
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costly ingredients, fish and water, thistle and mandrake, 
mandragora apple and root. The juice of the man- 
dragora apple was also used for analgesia but overdoses 
caused often untimely death, hence the nickname 
‘devil’s apple5. It contains the two belladonna alkaloids 
hyoscyamine and hyoscine with the parasympathicolytic 
properties mydriasis, bradycardia and reduced glan­
dular secretions, but also visual hallucinations, especial­
ly sensations of flying. The famous St, Anthony 
Tryptich (Lisbon, Museu Nacional de Arte Antiga) 
shows not only the temptations of St. Anthony, all ‘cold5 
treatments for ergotism including the mandragora apple 
and roots and suffering ergotants, but also strange flying 
aircrafts. Jeroen Bosch (1452-1516) painted all three in­
terior panels with outrageously strange and diabolic 
scenes, as if seen by a hallucinating brain. Ergot, when 
baked with dough, may be transformed into lysergic 
acid diethylamine (LSD), a known hallucinogen. 
Ergotants were therefore twice afflicted by hallucina­
tions: first by the transformed ergot alkaloids and then 
from the belladonna alkaloids from the mandragora 
[3,7,8,10].
4. Use of ergot as an oxytocic drug
Fig. 3. Woodcut by Hans Wâchtlin, StraBburg. 4Von der kalten 
Brandt’ in: Feldtbuch der Wundartzney, Hanns von GersdorfT (1517).
The European Renaissance may be defined as the 
transition from the medieval, mythical religious society 
to the modern world. For ergotism, the Middle Ages 
ended in 1582 when Adam Lonicer in Germany men­
tioned for the first time the use of ergot to stimulate 
uterine contractions of labour (‘pains of the womb5) by 
administering three sclerotia (containing 0.5 mg ergot). 
The first accurate description of the ergot is also from 
his Kreuter-buch: ‘long black hard narrow corn pegs, 
internally white, often protruding like long nails from
between the grains in the ear5 [2].
The honour of the first description in a medical jour­
nal is given to Paulizky in 1787. Ergot as ‘pulvis ad par- 
tum’ was prescribed by midwives and physicians alike. 
It showed an action which was ‘more rapid and power­
ful than any other known drug5 [11]. John Stearns from 
New York (1807) wrote in a famous letter to Mr, S. 
Akerly about the properties, dosage and side effects of 
ergot- [12], The crude ergot was given in a dosage of 
5-10 g to parturients resulting in a rapid and sudden ter­
mination of labour with an induction delivery time of 
not more than 3 h. However, this ‘pulvis parturiens’ was 
not suitable for accurate therapeutic administration be­
cause of the large variation of active ingredients and the 
severe adverse events like violent nausea and vomiting. 
Its use in labour induction ended in 1822 when Hosack 
from New York stated that many stillbirths were due to 
uterine rupture with resulting maternal death. The 
‘pulvis ad partum5 was renamed ‘pulvis ad mortem’ [13]. 
By the end of the 19th century its use as an oxytocic was 
virtually abandoned.
112 P.W.J. van Dongen, A. N.J. A. de Groot/Eur. J. Obstet. Gynecol. Re prod. Biol. 60 (1995) 109-116
5. Cause and prophylaxis of ergotism
The first suggestion that ergotism was caused by 
blighted grains was already mentioned in 1125. Caspar 
Schwenkfeldt (Poland, 1600) thought that the honey- 
dew of the rye was the cause of the ergot epidemics [3].
During an epidemic of gangrenous ergotism in 
Sologne (France, 1630), Tuilier Sr. did animal research 
by giving ‘cornicula nigra5 to chickens, geese and pigs: 
they all died. Unfortunately, he did not publish his re­
sults. Only in 1676, did Dodart with help from the son 
of Tuilier, solve the problems of the epidemiology and 
cause of the gangrenous ergotism. Likewise, Johann 
Brunner, described the cause of the convulsive type in 
1695 in Leipzig, Germany [3].
Although the cause of ergotism was known, it took 
more than a century to specify the first prophylactic 
measures by L’Abbé Tessier in 1778. A vast epidemic of 
gangrenous ergotism with more than 8000 victims in 
Sologne, France, was caused because the grains were not 
cleansed from ergot. He proposed drainage, cultivation 
of potatoes in stead of rye and the enforced cleaning of 
grains [14]. A second description of preventing ergotism 
by controlling the quality of bread in hospitals was 
elucidated by Johann Taube in his magnificent book 
‘Die Geschichte der Kriebelkrankheit’ (Gottingen, Ger­
many, 1782). Moreover, his clinical pictures of the 
neurologic and psychiatric disorders are still valuable 
today. His recommended treatments of ergotism were 
waterbaths at 20°C, electrotherapy and anthelmintic 
drugs [3].
The last epidemic of convulsive ergotism in Germany 
(Oberhessen) was eloquently depicted by Siemens in 
1879 [15]. He noted that neurological symptoms, like 
painful tonic contractions of the flexors, ataxy of the 
limbs, instability and epilepsy, always preceded 
psychiatric disturbances like decreased awareness, deli-
»
rium and hallucinations. Moreover, the damage proved 
to be irreversible (Table 1).
6. Analysis and mode of action of ergot alkaloids
Table 2
A choice of pharmaceutical constituents found in ergot alkaloids3
Although the word alkaloid is a misnomer, it is still 
used widely. Originally, alkaloids were described in 1913 
as 'basic substances occurring in plants’ [16]. Nowa­
days, nitrogenic constituents are included as well One 
may say that ergot is a 'treasure chest of valuable phar­
maceuticals' (Table 2, [2]).
The honour of the first person trying to analyse and 
isolate the active constituents of ergot goes to the phar­
macist Heinrich Wiggers (1835) in Gottingen, Germany 
[17]. However, after numerous systematic botanical and 
chemical investigations no fundamental discovery was 
made.
The first pure alkaloid was described in 1875 by 
Tanret in France [18]. The crystallized ergotinine was,
Acetylcholine
Agmatine
Amino-sulphonic acid
Betaine
Cadaverine
Choline
Ergobasine
Ergochrysin
Ergoclavine
Ergocornine
Ergocri stine
Ergokryptine
Ergoflavin
Ergometrine (ergonovine)
Ergosterol
Ergotamine
Ergotaminine
Ergoth ioneine
Ergotinine
Ergotocin
Ergotoxine
Guanosine
Histamine
Histidine
Iso-amylamine
Iso-leucine
Leucine
Putrescine
Sclerocrystallin (secalonic acid)
Secale cornutum
Sensibamine
Trimethylamine
Tyramine
Tyrosine
Uracil
Valine
X-alkaloid (ergostetrin)
aThe four alkaloids ergometrine, ergobasine, X-alkaloid and 
ergotocin are identical (see text).
however, almost inert. Sollmann and Brown [19] studied 
in 1905 the circulatory effects in mammals after both 
intravenous and intramuscular injections of crude ergot. 
The results varied considerably because of differences in 
the preparations and hence the dosages of ergot. Even 
after destruction of the spinal cord the same pattern of 
a rapid drop of blood pressure followed by a prompt re­
covery of the blood pressure was noted, but only after 
intravenous injection of ergot and not after oral admin­
istration. The response to adrenalin (hypertension) was 
decreased by ergot. The adrenergic blockade by ergot is 
therefore first described by Sollmann [19] and not by 
Barger as stated in his extensive monograph [1]. Barger 
and Carr [20] obtained two impure fractions from
ergotinine. The uterotonic activity was attributed to a 
single alkaloid, the so-called ergotoxine.
Ergotamine was developed as a new physiologically 
active agent in 1920 [21,22]. Its uterotonic properties are 
easily lost during storing [23]. At present, ergotamine is 
only used in the treatment of migraine and other vascu­
lar headaches. When inadvertently given during preg­
nancy it may cause fetal stress. A review of all side 
effects of ergot alkaloids during pregnancy has been 
published elsewhere [24].
Uterine action after oral administration of extract of 
ergot (according to the British Pharmacopoeia) was 
monitored externally in 1927. It was found to be wholly 
inert, as was the extract according to the U.S. Phar­
macopoeia [25]. Ergotamine or ergotoxine exerted a 
prolonged action and were therefore considered to be 
ideal agents for use after delivery. However, it took 
4-10 min after intravenous injection before any 
uterotonic action was noted, 20 min after intramuscular
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Fig. 4. Tracing of uterine contractions made on sixth day of puerperium by intra-uterine bag method, showing the effect of oral 0,5 mg ergometrine. 
The arrow shows moment of administration. (Fig. 1 from Dudley and Moir [29] 1935. Reproduced with permission of British Medical Journal),
injection, and even 35 min or longer after oral adminis­
tration.
In their classic paper of 1932, Moir and Dale used the 
same technique for intra-uterine pressure recording as 
Schatz in 1872 [26] and Bourne and Burn in 1927 [25]: 
a sterilized bag was inserted in the puerperal uterus, con­
nected by tubing to a mercury maraometer and to a 
rotating drum with a recording device [27-28]. When an 
aqueous extract of ergot was given orally to a postpar­
tum woman, the effect appeared not only in a 
remarkably short time of 4 min, but also strikingly dif­
ferent to that seen after administration of ergotamine or 
ergotoxine. The contractions were more frequent 
(2-3/min), more regular, with greater amplitude and rise 
of the basal intra-uterine pressure than observed after 
administration of any other drug. Therefore, it was con­
cluded that another and more powerful uterotonic agent 
must be present. Indeed, a water-soluble alkaloid was 
isolated in 1935 by the same group and henceforth called 
ergometrine [29]. The properties were described as 
follows: ‘the onset is sudden, and accompanied by pro­
nounced uterine spasm, which appears to be caused by 
a succession of contractions so rapid that the organ as 
a whole has no time to relax. This stage lasts for about 
1 h, and is followed by a second stage, during which the 
uterus shows regular, vigorous, isolated contractions,
continuing for 1 h or more5. Oral administration of 0.5 
mg ergometrine provoked, after an interval of 6.5-8 
min, contractions identical with those produced by the 
aqueous extracts of ergot as described in 1932 [27] (Fig. 
4). Therefore, the active substance of ergot extract must 
be ergometrine. After intramuscular or intravenous ad­
ministration of ergometrine the sudden action was 
recorded after 4 and 2 min, respectively.
Within a month, three other groups — two in the 
USA [23,30,31] and one in Switzerland [32] — described 
the same alkaloid, although by different names: 
ergotocin [30,31], ergostetrin [23] and ergobasine [32]. 
The four alkaloids proved to be the same substance. In 
the United Kingdom it adopted the name ergometrine; 
a fifth name ergonovine was selected for use in the USA.
7. Chemistry of ergometrine, its derivatives and bromo­
criptine
All naturally occurring alkaloids are derived from 
lysergic acid and contain a substituent at position 8 (Fig. 
5; [33]). Two groups are described with different target 
organs, pharmacological properties and side effects. 
Ergometrine is the simplest compound with a single 
amine group as substituent (Fig. 5). Upon hydrolysis, 
ergometrine yields lysergic acid and an amine; conse-
HOOC 11 15
8 10 I r
7 c 3 ?
CH 3
ch3chnh • oc
ch2oh
CH3
Fig. 5, Structural formulae of lysergic acid (left) and ergometrine (right) (Reproduced with permission from C.V. Mosby Company, Goth 1964, 
Medical Pharmacology).
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quently it is designated as amine alkaloid. Methylergo- 
metrine is a semi-synthetic amide derivative of d-lysergic 
acid. It contains an extra methyl group in the substituent 
at position 8. (Methyl-)ergometrine has greater 
uterotonic than vasoconstrictive abilities [24].
The partial synthesis of ergometrine by Stoll and Hof­
mann in 1938 [34] was followed by the synthesis of 
lysergic acid diethylamide (LSD) in 1943 by Hofmann. 
It proved to be more toxic and less uterotonic than 
ergometrine. Within 40 min after swallowing an over­
dose, Hofmann himself experienced dizziness, unrest, 
difficulty in concentration, visual disturbances and 
‘delusional insanity’, as was described in the old 
epidemics of ergotism (Table 1). It was shown that the 
hallucinogenic activity resulted from serotonine (5- 
hydroxy-tryptamine)-antagonism [35].
The amino acid alkaloids comprise the naturally 
occurring ergotamine and ergotoxine and the semi­
synthetic bromocriptine. Prolactin secretion inhibition 
is caused by the a-ergokryptine compound. The syn­
thesis of bromocriptine (2-bromo-a-ergokryptine) in 
1965 heralded the new era of dopamine receptor stimu­
lation. Interestingly, it is known that during epidemics 
of ergotism the milk production of nursing mothers and 
cows stopped. Ergot extracts were also used in the 19th 
century to treat amenorrhoea [33]!
8» Management of the third stage of labour with ergot 
alkaloids
The World Health Organization (WHO) estimates 
that each year at least 500 000 women die from causes 
related to pregnancy and childbirth [36]. Postpartum 
haemorrhage (PPH) is one of the most common causes 
of maternal death, amounting to 13% of all maternal 
deaths in developed and 33% in developing countries 
[37]. The calculated maternal mortality rate (MMR) in 
the British Isles in the 18th century was about 2000 per 
100 000 live births. William Smellie decribed PPH in 
1751 as follows: 'all women, when the placenta 
separates, and after it is delivered, lose more or less red 
blood from the quantity of 1/2 lb to that of 1 lb or even 
2; but should it exceed this proportion and continue to 
flow without diminuition, the patient is in great danger 
of her life5 [38]. The MMR in the United Kingdom in 
1930 was still 300/100 000 live births. Nowadays, in
Western Europe and North America this figure is about 
8/100 000 live births [36].
The tremendous decrease in MMR is due to improved 
social-economic factors and introduction of antibiotics, 
blood transfusion facilities and oxytocic drugs. The ac­
tive management in the third stage of labour and treat­
ment of excessive blood loss in the so-called 4th stage of 
labour (after expulsion of the placenta) by administering 
oxytocics has been decribed as 4 one of the enduring 
achievements of modern science5 [36]. After administer­
ing ‘secale luxurians’ after birth, Schwenkfeldt in 1600
noted for the first time in history that ‘sanguinem sistere 
vulgus credit’, i.e. ‘one believes it will stop the bleeding’ 
[3]. The 'Guide to midwifery’ from 1912 recommends an 
intramuscular injection of ergotine after the birth of the 
infant [39].
The first application of ergometrine as a prophylactic 
drug is attributed to Browne in 1935, but it was publish­
ed in 1947 [40], Ergometrine (0.5 mg) was given in­
tramuscularly to 500 consecutive normal cases as soon 
as the head was delivered. However, results of blood loss 
are not given — it is only stated that no cases were seen 
with manual removal of the placenta.
Joyce and Lennon studied 156 cases with PPH be­
tween 1938 and 1947. They advocated that if PPH oc­
curred before delivery of the placenta, 0.5 mg 
ergometrine should be given intramuscularly by ‘the 
midwife while awaiting the doctor’s arrival’ [38]. Shaw 
(1949) noted that the duration of the third stage was 
markedly reduced. Moreover, less blood transfusions 
were needed if a manual placental removal was done 
after prophylactic intravenous injection of ergometrine 
(54% vs. 8%) [41].
Daley (1951) is the first to routinely administer 0.5 mg 
ergometrine intramuscularly in normal parturients (490 
vs. 510 controls) as the head was crowned. The blood 
loss was carefully measured. A significant reduction in 
the duration of the third stage of 4 min afid in blood loss 
of 70 mis was established. However, the most important 
finding was that the frequency of PPH — defined as 
blood loss > 560 mis — was significant less in the 
ergometrine group (9.2%) compared to the control 
group (15.7%) [42].
At present, evidence of the effectiveness of active 
management with oxytocic drugs is based on meta­
analysis of randomized controlled trials. Prescribing any 
oxytocic drug routinely for the prevention of PPH 
resulted in significantly decreased blood-loss, less blood 
transfusions, lower incidence of PPH (from 10%-6%)> 
shortened third stage of labour and decreased need for 
further administration of oxytocics [43-46]. No 
statistical differences in the incidence of PPH was found 
after administration of oxytocin, ergometrine or pro­
staglandins [45-47], However, it is very clear that 
ergometrine may provoke unpredictably severe hyper­
tension, nausea, vomiting and many more side effects 
due to its vasoconstrictive effects [24], sometimes 
leading to maternal deaths [50]. Moreover, there is 
ample evidence that both oral and parenteral 
ergometrine is not stable under humid, warm and light 
conditions [49-53]. It was therefore concluded that the 
best choice for use in the third stage of labour is not 
ergometrine but oxytocine [54].
9. Conclusion
We may have come full circle, from the accidental poi­
soning with ergot alkaloids (ergotism), acceleration of
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labour, prevention and treatment of PPH, to the knowl­
edge of the severe side effects and instability of 
ergometrine. Perhaps the time has come to abandon 
ergometrine from obstetrics. Primum est non nocere.
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